Clinical trials: Locally Advanced Disease
Rectal Cancer
Benchmarking Trial Between France and Australia Comparing Management of Primary Rectal Cancer Beyond TME (Total Mesorectum Excision) and Locally Recurrent Rectal Cancer
The incidence of rectal cancers is at 15,000 new cases per year in France of which 10 to 15% are locally advanced (T4bNxM0) at the moment of diagnosis.
- Trial name
- PELVICARE (NCT02551471)
- Testing
- Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging), MDT (Multidisciplinary team) meeting observation, Semi-structured exploratory interviews and focus group with MDT health professional attendees
- Where
- 12 sites in Australia, France
- Volunteers
- 165 people
- Sponsor
- University Hospital, Bordeaux
Non-Small Cell Carcinoma of Lung
Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.
Current oncological treatment for patients with locally advanced lung cancer comprise adjuvant immunotherapy (immune checkpoint inhibitors-ICI) as an additional one-year treatment after chemoradiotherapy which increases overall…
- Trial name
- NCT07754409
- Where
- Sweden
- Volunteers
- 75 people
- Sponsor
- Göteborg University
Colorectal Neoplasms
Brazilian Total Neoadjuvant Therapy Trial
Standard therapy for localized rectal cancer includes chemotherapy and radiation therapy, followed by a "recovery" period of 7-12 weeks, surgery and adjuvant chemotherapy for 3-6 months.
- Trial name
- BRAZIL-TNT (NCT05081687)
- Testing
- Folfirinox
- Where
- Brazil
- Volunteers
- 150 people
- Sponsor
- Hospital Israelita Albert Einstein
Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
This phase Ib trial tests the side effects and best dose of minnelide when given together with osimertinib for the treatment of non-small cell lung cancer that has spread to other places in the body (advanced) and has a change…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05166616
- Testing
- Biopsy, Osimertinib, Triptolide Analog
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Esophageal Carcinoma
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally advanced esophageal squamous cell carcinoma…
- Trial name
- NCT05937438
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital
Pancreatic Cancer
A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)
The purpose is to assess the overall survival of patients receiving either UFT/LV + radiotherapy (RT) or UFT/LV + Cetuximab + RT after neo-adjuvant chemotherapy.
- Trial name
- PERU (NCT01050426)
- Testing
- UFT, Leucovorin, UFT/ Leucovorin + Cetuximab + Radiotherapy
- Where
- 8 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body…
- Trial name
- PETRA (NCT01805908)
- Testing
- 111In-Pertuzumab + SPECT-CT
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Muscle Invasive Upper Tract Urothelial Carcinoma
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual…
- Trial name
- NCT05595408
- Testing
- Adjuvant chemotherapy, adjuvant immunotherapy
- Where
- China
- Volunteers
- 84 people
- Sponsor
- RenJi Hospital
Colorectal Cancer
Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Intensity-modulated radiation therapy (radiation directed at the tumor more precisely than in standard radiation therapy) with incorporated boost (an…
- Trial name
- NCT00084591
- Testing
- capecitabine, conventional surgery, neoadjuvant therapy
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Breast Neoplasms
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
This is a pilot phase 1b study to investigate the safety and side effects of combining the ROR1-targeting monoclonal antibody, cirmtuzumab, with paclitaxel for patients with HER2 negative, metastatic breast cancer.
- Trial name
- NCT02776917
- Testing
- Cirmtuzumab + Paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Barbara Parker, MD
Cervical Cancer, Cancer
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
This was a multicenter, open-label, 2-part randomized study of MEDI4736 administered as monotherapy or in combination with ADXS11-001 to participants with recurrent/persistent or metastatic squamous or non-squamous carcinoma of…
- Conditions
- Cervical Cancer, Cancer, Head and Neck Cancer
- Trial name
- NCT02291055
- Testing
- ADXS11-001, MEDI4736
- Where
- 17 sites in United States
- Volunteers
- 75 people
- Sponsor
- Advaxis, Inc.
Breast Neoplasms
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.
- Trial name
- NCT00034125
- Testing
- LY353381, tamoxifen
- Where
- 11 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Advanced Cancers
BiPAP-Vapotherm RCT
The goal of this clinical research study is to learn if 3 breathing devices reduce feeling short of breath in cancer patients. Researchers also want to learn if these devices can help to control shortness of breath.
- Trial name
- NCT01518140
- Testing
- Oxygen Delivery Devices, Questionnaires
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced or Metastatic Breast Cancer
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
This study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival…
- Trial name
- NCT07235618
- Testing
- Entinostat, Fulvestrant
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Carcinoma of Lung, Locally Advanced
Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC
This is a prospective, single-arm phase II clinical study enrolling patients with locally advanced unresectable non-small cell lung cancer.
- Trial name
- NCT07882940
- Testing
- Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer, Rectal Adenocarcinoma
Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment
The purpose of this project is to obtain important information about the tumour and surrounding organs during preoperative chemo-radiotherapy for patients with adenocarcinoma of the rectum.
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Locally Advanced Malignant Neoplasm
- Trial name
- AMPERE (NCT03619668)
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Aalborg University Hospital
Rectal Cancer
Avelumab With Chemoradiation in Locally Advanced Rectal Cancer
This trial is investigating the inclusion of avelumab post long-course chemo-radiotherapy in patients with resectable locally advanced rectal cancer.
- Trial name
- NCT03299660
- Testing
- Avelumab, 5 Fluorouracil, Capecitabine Pill
- Where
- 7 sites in Australia
- Volunteers
- 37 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
This phase II trial studies how well paclitaxel and carboplatin before radiation therapy with paclitaxel works in treating human papillomavirus (HPV)-positive patients with stage III-IV oropharynx, hypopharynx, or larynx cancer.
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT02048020
- Testing
- paclitaxel, carboplatin, intensity-modulated radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Pancreatic Cancer
Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer
The safety and efficacy of combination of SBRT with sequential S-1 in treating patients with locally advanced pancreatic cancer and poor medical conditions will be evaluated.
- Trial name
- NCT02704143
- Testing
- combination of Cyberknife with S-1
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Changhai Hospital